Skip Navigation

Rheumatology 2008 47(Supplement 5):v5-v7; doi:10.1093/rheumatology/ken275
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sgonc, R.
Right arrow Articles by Wick, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sgonc, R.
Right arrow Articles by Wick, G.
Related Collections
Right arrow Systemic Sclerosis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

This article appears in the following Rheumatology issue: Update in systemic sclerosis [View the issue table of contents]

Pro- and anti-fibrotic effects of TGF-β in scleroderma

R. Sgonc1 and G. Wick1,2

1Division of Experimental Pathophysiology and Immunology and 2Laboratory of Autoimmuity, Biocenter, Medical University of Innsbruck, Innsbruck, Austria.

Correspondence to: G. Wick, Division of Experimental Pathophysiology and Immunology, Laboratory of Autoimmunity, Biocenter, Medical University of Innsbruck, Peter-Mayr-Straße 4a, A-6020 Innsbruck, Austria. E-mail: georg.wick{at}i-med.ac.at


  Abstract

The University of California at Davis 200 and 206 (UCD-200/206) lines of chickens have proven to be the animal model that best reflects the situation in human SSc. We have demonstrated a misbalance of pro-fibrotic (TGF-β1) and anti-fibrotic (TGF-β2 and -β3) TGF-β isoforms as a possible cause for fibrotic alterations in this model. This opens new avenues for diagnosis and therapy for this still intractable condition.

KEY WORDS: Systemic sclerosis, Transforming growth factor-β1, Transforming growth factor-β2, Transforming growth factor-β3, Fibrosis, The University of California at Davis 200 chicken

Submitted 30 April 2008; Accepted 19 June 2008


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.